Nicotine vaccines for smoking cessation

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Hatsukami, Dorothy ^a   Cahill, K ^b   Stead, L F ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE VACCINE;

DRUG EFFICACY; DRUG USE; HUMAN; INTERVENTION STUDY; OUTCOME ASSESSMENT; RELAPSE; REVIEW; SMOKING CESSATION;

EID: 44949091553     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007072     Document Type: Review

References (27)

1. Balfour 2004 Balfour DJK. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus. Nicotine & Tobacco Research 2004;6(6):899-912.
2. Cahill 2007 Cahill K, Stead LG, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1.Art. No.: CD006103. DOI:10.1002/14651858.CD006103. pub2.
3. Deeks 2006 Deeks JJ, Higgins, JPT, Altman DG, editors. In: Higgins JPT, Green S, editors. Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 8. The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd 2006.
4. Fagerstrom 2005 Fagerstrom K, Balfour DJK. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opinion on Investigational Drugs 2005;15(2):107-16.
5. Haney 2004 Haney M, Kosten TR. Therapeutic vaccines for substance abuse. Expert Review of Vaccines 2004;3:11-18.
6. Harvey 2004 Harvey DM, Yasar S, Heishman SJ, Panlilio LV, Henningfield JE, Goldberg SR. Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl) 2004;175:134-42.
7. Hatsukami 2005 Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, de Vos A, et al.Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clinical Pharmacology and Therapeutics 2005;78(5):456-67.
8. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;7414:557-60.
9. Higgins 2006 Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. http://www.cochrane.org/resources/handbook/hbook.htm(accessed 15th November 2006).
10. Hughes 2007 Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1.Art. No.: CD000031. DOI:10.1002/14651858.CD000031.pub3.
11. Lancaster 2004 Lancaster T, Stead LF. Physician advice for smoking cessation. Cochrane Database of Systematic Reviews 2004, Issue 4.Art. No.: CD000165. DOI:10.1002/14651858.CD000165.pub3.
12. Lancaster 2005 Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database of Systematic Reviews 2005, Issue 3.Art. No.: CD001292. DOI:10.1002/14651858.CD001292. pub2.
13. Laviolette 2004 Laviolette SR, van der Kooy D. The neourobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nature Reviews: Neuroscience 2004;5:55-65.
14. LeSage 2006 LeSage MG, Keyler DE, Pentel PR. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. American Association of Pharmaceutical Scientists Journal 2006;8(1):E65-E75.
15. NicQb 2007 Cytos Biotechnology AG. NicQb. http://www.cytos.com/ default3.asp?text=products_pipeline.asp&bot=bot_products.htm (accessed 23rd November 2007) 2007.
16. NicVAX 2007 Nabi Biopharmaceuticals. NicVAX. http://www.nabi.com/ pipeline/pipeline.php?id=3 (accessed 23rdNovember 2007) 2007.
17. Orson 2007 Orson FM, Kinsey BM, Singh RAK, Wu Y, Gardner T, Kosten TR. The future of vaccines in the management of addictive disorders. Current Psychiatry Reports 2007;9(5):381-7.
18. Pentel 2000 Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, et al.A nicotine conjugate vaccine reduces nicotine distribution to brain and attentuates its behavioral and cardiovascular effects in rats. Pharmacology Biochemistry and Behavior 2000;65(1):191-8.
19. Pentel 2004 Pentel PR. Vaccines and depot medication for drug addiction: rationale, mechanisms of action, and treatment implications. In: HarwoodH, MyersT editor(s). New treatments for addiction: behavioural, ethical, legal and social questions. Washingto DC: National Academies Press, 2004.
20. Scherer 1999 Scherer G. Smoking behavior and compensation: a review of the literature. Psychopharmacology 1999;145:1-20.
21. Siu 2007 Siu ECK, Tyndale RF. Non-nicotinic therapies for smoking cessation. Annual Review of Pharmacology and Toxicology 2007;47:541-64.
22. Stead 2005 Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database of Systematic Reviews 2005, Issue 3.Art. No.: CD001007. DOI:10.1002/14651858.CD001007.pub2.
23. Stead 2006 Stead Lf, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database of Systematic Reviews 2006, Issue 3.Art. No.: CD002850. DOI:10.1002/14651858.CD002850.pub2.
24. Stead 2008 Stead LF. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2008, Issue 1.Art. No.: CD000146. DOI:10.1002/14651858.CD000146.pub3.
25. Stolerman 1995 Stolerman IP, Jarvis MJ. The scientific case that nicotine is addictive. Psychopharmacology (Berl) 1995;117:2-10; 14-20.
26. TA-NIC 2007 Celtic Pharma. TA-NIC. http://www.celticpharma.com/ theportfolio/ta-nic.html (accessed 23rd November 2007) 2007.
27. WHO 2006 World Health Organization. WHO Framework Convention on Tobacco Control: why is it important?. http://www.who.int/features/qa/34/en/ print.html (accessed 24th November 2007) 2006.